Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIMOSA: Abagovomab Maintenance in Ovarian Cancer
NCT00418574Phase 3Terminated
- Sponsor
- Menarini Group
- Start
- Dec 2006
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 9
01
Overview
A Phase 3 trial of abagovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Menarini Group. Started Dec 2006; status: terminated.
02
Drugs
abagovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00418574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418574.